Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11207MR)

This product GTTS-WQ11207MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF18 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_004195.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8784
UniProt ID Q9Y5U5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11207MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3750MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ4908MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ8555MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ15114MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ1973MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ15732MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ13445MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ6582MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW